No Prescription |
 |
 | ||
|
Diltizem SR Zemtard |
|
| ||
No Prescription » Prescription Drugs 6 » Diltizem SR Zemtard Product Origin: EU (Turkey)This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.Medical Information:Diltiazem capsules contain the active ingredient diltiazem which is a type of medicine called a calcium channel blocker. This type of medicine acts on the heart and blood vessels.Diltiazem works by slowing down the movement of calcium through muscle cells that are found in the heart and the walls of blood vessels. It does this by blocking 'calcium channels' on these muscle cells. Calcium is needed by the muscle cells in order for them to contract. By depriving them of calcium diltiazem causes the muscle cells to relax. This action of diltiazem has two main effects; it slows down the rate at which the heart beats and it allows the blood vessels in the body to widen. When the heart beats more slowly the pressure at which the blood is pumped out of the heart is reduced. When the blood vessels in the body relax and widen this decreases the resistance that the heart has to push against in order to pump the blood around the body. Both these actions reduce the pressure within the blood vessels. This means diltiazem can be used to lower high blood pressure. Slowing the heart rate also reduces the energy used by the heart to pump blood around the body. This in turn reduces the heart's need for oxygen. At the same time widening the blood vessels improves the blood and therefore oxygen supply to the heart. Both these features mean that diltiazem can be used in the management of angina. The chest pain of angina is caused by insufficient oxygen supply to the heart. As diltiazem improves this oxygen supply and also reduces the effort the heart has to make to pump blood it can be used to prevent angina attacks. Diltiazem capsules are a long-acting or 'modified-release' form of diltiazem. This means that they are designed to release the diltiazem slowly and continuously over several hours to produce a steady blood level of the medicine throughout the day. Diltiazem capsules are designed to be taken once a day at the same time each day. They should be swallowed whole and not chewed or crushed as this would damage the modified-release action. What is it used for?Angina pectoris.Mild to moderate high blood pressure (hypertension). Buy Diltizem SR Zemtard and other Prescription Drugs 6 products online at Medstore. Buy Online at Medstore - Click Here!
About Diltizem SR Zemtard: Product Type: Prescription Drugs 6 Diltizem SR ( Zemtard Viazem XL Tildiem LA Dilzem XL Calcicard Angitil XL Dilcardia Generic Diltiazem HCl ) Diltizem SR (Zemtard Viazem XL Tildiem LA Dilzem XL Calcicard Angitil XL Dilcardia Generic Diltiazem HCl) Zemtard Viazem XL Tildiem LA Dilzem XL Calcicard Angitil XL Dilcardia Generic Diltiazem HCl 120 mg 48 tabs 240 mg 16 tabs Zemtard Viazem XL Tildiem LA Dilzem XL Calcicard Angitil XL Dilcardia Generic Diltiazem HCl Diltizem SR
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
